Card image

Advances in the Treatment of Noninfectious Uveitis with Biologics: Anti-TNF and Beyond

Advances in the Treatment of Noninfectious Uveitis with Biologics: Anti-TNF and Beyond

Advances in the Treatment of Noninfectious Uveitis with Biologics: Anti-TNF and Beyond

  • Editor: Dr. Marina Mesquida
  • No of Pages: 72
  • Publisher: OMICS International
  • Published On: February 2014 , Wed 26
  • Chapter 1      
    Immunopathology of Non-Infectious Uveitis: General Concepts of Immunity and Autoinflammatory Response
    Authors: Marina Mesquida, Blanca Molins, Núria Mendieta

    Non-infectious uveitis comprehends a heterogeneous group of intraocular inflammatory diseases that arise without a known infectious trigger.

  • Chapter 2      
    Treatment Strategies in Non- Infectious Uveitis: General Concepts
    Authors: David Díaz-Valle, Rosalía Méndez-Fernández

    The term uveitis refers to a group of inflammatory disorders affecting the uvea, the middle layer of the eye.

  • Chapter 3      
    Classical Immunosuppressive Therapies for Non-Infectious Uveitis
    Authors: Alex Fonollosa, Joseba Artaraz

    The first therapeutical option in uveitis is corticosteroids.

  • Chapter 4      
    Tumor Necrosis Factor Alpha (TNF-α) Antagonists
    Authors: Marina Mesquida

    Tumor necrosis factor alpha (TNF-α) is a pleiotropic cytokine expressed in a wide variety of inflammatory conditions contributing

  • Chapter 5      
    Interferons: IFN-α
    Authors: Miguel Cordero Coma, Raquel Salazar

    Interferon (IFN) was first described in 1957 by Isaacs and Lindenmann

  • Chapter 6      
    IL-2 Receptor Antagonists: Daclizumab
    Authors: Ariel Schlaen, Cristóbal Couto

    Daclizumab is the humanized form of IgG1 monoclonal antibody directed against the 55 kDa alpha subunit of the IL-2 receptor

  • Chapter 7      
    IL-6 Receptor Antagonist: Tocilizumab
    Authors: Anna Leszczynska

    Interleukin-6 (IL-6) is a key cytokine featuring redundancy and pleiotropic activity

  • Chapter 8      
    IL-1β Antagonists: Anakinra, Rilonacept, Canakinumab, Gevokizumab
    Authors: Maite Sainz de la Maza

    Noninfectious uveitis has a complex and multifactorial etiology that involves the breakdown of the blood-eye and bloodretinal barriers

  • Chapter 9      
    T-Cell Co-stimulation Modulator: Abatacept
    Authors: Víctor Llorenç

    Abatacept (Orencia, Bristol-Myers Squibb Company, Princeton NJ, USA) is a fusion protein composed of the Fc region

  • Chapter 10      
    Anti-CD 20
    Authors: Laura Pelegrín, José Hernández-Rodríguez

    Rituximab (RTX) is a chimeric human-mice monoclonal antibody directed against the surface marker CD20 of pre-B lymphocytes

  • Chapter 11      
    Safety Issues: What to do Before Initiating and during Biological Therapy
    Authors: Gerard Espinosa

    The rate of biologic therapies use in patients with non-infectious uveitis is rising rapidly

  • Chapter 12      
    Safety Issues: Principal Adverse Events Related to Biological Therapy
    Authors: María Victoria Hernández, Raimon Sanmartí

    In the last decade, the use of biological therapy, mainly tumor necrosis factor (TNF) antagonists

  • Chapter 13      
    Emerging Therapies: Fingolimod, Secukinumab, and Efalizumab
    Authors: Marc Figueras-Roca

    This chapter is intended to provide a short glimpse on recent emerging therapies that could play an important role in the field

  • Dr. Marina Mesquida

    Uveitis Unit, Ophthalmology Department, Hospital Clínic de Barcelona, Sabino Arana, 108028, Barcelona, Spain

Follow us on